ArticleArthritis care & research2026
Systemic Lupus Erythematosus Mortality Among Decedents Aged ≥15 Years-United States, 2018-2023.
Article in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSystemic lupus erythematosus (SLE) is a chronic autoimmune condition that can lead to death. To examine SLE as an underlying and contributing cause of death, the Centers for Disease Control and Prevention (CDC) analyzed 2018 to 2023 mortality data for persons aged ≥15 years overall and by age, sex, race and ethnicity, and region.
methodsDeath certificate data for persons aged ≥15 years with any mention of SLE (International Classification of Diseases, Tenth Revision [ICD-10] code M32) were analyzed using the CDC Wide-ranging Online Data for Epidemiologic Research (WONDER) system. We calculated age-adjusted death rates and assessed patterns by sex, age, race and ethnicity, and region. Underlying and contributing causes of death were evaluated using ranked cause-of-death lists and ICD-10 subchapters.
resultsDuring 2018 to 2023, 14,936 deaths had any mention of SLE listed on the death certificates. Of these deaths, 6,414 (42.9%) listed SLE as the underlying cause. The age-adjusted SLE mortality rate per million population was greater among females (5.97) than males (1.16), non-Hispanic African American persons (10.70) than persons of other non-Hispanic racial groups (range 2.46-5.62), Hispanic persons (3.98) than non-Hispanic persons (3.59), and people in the South (4.37) than people in other regions. When SLE was listed as a contributing cause of death, the leading underlying causes were heart disease (0.93), cancer (0.56), and COVID-19 (0.51). The overall age-adjusted SLE mortality rates were significantly higher in 2020 and 2021 than in all other study years, indicating the likely impact of the COVID-19 pandemic on SLE mortality.
conclusionOverall management of SLE, comorbidities, and infections in patients with SLE, as well as interventions targeting groups (eg, African American persons) disproportionately impacted by SLE, may reduce overall SLE mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.